PHERGain-2 shows meaningful HRQoL preservation, expected HP/T-DM1 toxicity, and an outstanding pCR rate comparable with standard chemotherapy plus HP regimens in this patient population.

P1, N=31, Completed, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Completed | Trial completion date: Jul 2026 --> Feb 2026

Chemotherapy was the first-line regimen in 83 of 162 patients (51%), endocrine monotherapy in 55 of 162 (34%), and trastuzumab-pertuzumab-taxane or cyclin-dependent kinase 4 and 6 inhibitor-based regimens in eight of 162 (5%). 87534309); Center for Global Health at the United States-National Cancer Institute at the National Institutes of Health (contract award No. HHSN2612010000871/NO2-PC-2010-00087); Fogarty International Center, NIH, HHS; and Susan G. Komen for the Cure; in Argentina, Instituto Nacional del Cáncer (Ministry of Health), Fundación Argentina de Nanotecnología, Agencia Nacional de Promoción Científica y Tecnológica, CONICET (Ministry of Science, Technology, and Productive Innovation); Brazil, Ministério da Saúde (Ministry of Health); Chile, Instituto de Salud Pública (Public Health Institute) and Ministerio de Salud (Ministry of Health); and Mexico, Consejo Estatal de Ciencia y Tecnología de Jalisco (COECYTJAL) and Universidad de Sonora (University of Sonora).

P2, N=100, Recruiting, University of Kansas Medical Center | Not yet recruiting --> Recruiting

P2, N=54, Not yet recruiting, National Taiwan University Hospital

In patients with HER2-positive breast cancer treated with pertuzumab-based neoadjuvant therapy, treatment response appears to be primarily influenced by clinicopathological and treatment-related factors rather than systemic inflammatory status. Peripheral blood inflammatory biomarkers derived from routine laboratory parameters showed limited value in predicting pCR in this setting.

This retrospective single-center study included 75 patients with HER2-positive invasive breast cancer treated with neoadjuvant chemotherapy plus dual anti-HER2 blockade (trastuzumab and pertuzumab). Given the modest discriminative performance and lack of external validation, these findings should be interpreted cautiously. Further validation in larger independent cohorts is required before the score can be considered for clinical stratification or implementation.

We report a 51-year-old woman with prior hormone receptor-negative, human epidermal growth factor receptor 2-positive breast invasive ductal carcinoma (bilateral mastectomy, adjuvant trastuzumab/pertuzumab, radiation) who developed abrupt painful erythematous nodules of both legs and progressive polyarthralgia of the hands, knees, and ankles. Coordinated multidisciplinary care, oncology-directed chemotherapy, interventional pain management, and psychological support, improved pain control and mobility. This case adds to the limited pancreatitis, panniculitis, and polyarthritis literature and highlights that absent gastrointestinal symptoms can delay diagnosis; early recognition and collaborative management are essential in malignant pancreatitis, panniculitis, and polyarthritis presentations.

Pertuzumab retreatment was not associated with clinically meaningful deterioration in HRQoL. These findings support the use of dual HER2 blockade beyond progression in appropriately selected patients.

Hormone positivity (estrogen and or progesterone) were associated with poor survival First-line PTH demonstrated prolonged survival and high response rates in this Indian cohort, with manageable toxicity. These real-world findings support its feasibility and effectiveness in LMIC settings.

The combination of P + T met prespecified criteria to declare a signal of activity in patients with UC with ERBB2/3 alterations, but not in patients with OC/FTC.